We report a case with immunoglobulin A (IgA) 
Introduction

Recently, bone marrow transplantation (BMT) has been performed not only for patients with hematological malignancy but also for patients with severe autoimmune diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis and juvenile idiopathic arthritis. This therapy has been reported to improve the signs and symptoms in some cases with severe autoimmune diseases (1-3). These facts implicate that bone marrow cells, most likely including peripheral blood stem cells (PBSC), play an important role in the immune system.
BMT has shown evidence to attenuate kidney diseases including lupus nephritis (4) and immunoglobulin A (IgA) nephropathy (5) in experimental models. Moreover, PBSC differentiates to renal resident cells and contributes to the improvement of glomerular injury (6, 7) . Therefore, these observations suggest that BMT is of therapeutic benefit to glomerulonephritis, even in humans.
Herein, we report a case of IgA nephropathy, in whom mesangial IgA deposits disappeared after treatment with allogeneic peripheral blood stem cell transplantation (PBSCT) followed by immunosuppression therapy for acute lymphocytic leukemia (ALL). showed total obsolescence in 7 out of 13 glomeruli. Fibrocellular crescent was detected in 3 glomeruli. In the other glomeruli, mild mesangial proliferation and increased mesangial matrix were observed. Capillary wall thickening was not clear under light microscopy (Fig. 1a) . Immunofluorescence findings showed IgA deposition in mesangial areas (Fig. 1b) . Electron microscopy demonstrated electron dense deposits in the paramesangial area (Fig. 1c) (Fig. 2a) (Fig. 2b) . Electron microscopy demonstrated the disappearance of electron dense deposits in paramesangial area (Fig. 2c) .
. Crescent formation was not detected. No deposit of IgA and C3 was seen in immunofluorescence findings
In December 2004, his ALL relapsed. Initial therapy with cytotoxic antitumor agents and second PBSCT from his father was performed. However, he did not respond to these treatments and died with full leukemia. In the necropsy specimen of his kidney, deposit of IgA in mesangial area was not detected (data not shown).
Discussion
IgA nephropathy recurred in the grafts, which were transplanted in patients with endstage renal disease (ESRD) due to IgA nephropathy in some cases (8). Conversely, the deposition of IgA in the mesangial area disappeared in grafts, which were transplanted in patients with ESRD unrelated to
IgA nephropathy (9) . These results suggested that some circulating factors may play an important role for IgA nephropathy. Moreover, it has been reported that the decrease of IgA-specific suppressor T cell activity and the increase of IgA-specific helper T cell activity contribute to the pathogenesis of IgA nephropathy (10) . Recently, novel insights have been obtained in the structural and functional abnormality of underglycosylated IgA1 molecules (11, 12 (1) (2) (3) .
In experimental models, BMT has been reported to improve glomerulonephritis such as murine lupus nephritis (4) and IgA nephropathy (5 To date, PBSC has been reported to differentiate into numerous cell types such as hepatocytes (13) , neurons (14) , cardiomyocytes (15) , skin (16) , and endometrial cells (17) . (18) 
As for the kidney, some reports indicate that PBSC participates in the turnover of renal resident cells and contributes to renal regeneration. In the models of anti-thy1 antibodymediated glomerulonephritis, PBSC were reported to differentiate into endothelial cells and mesangial cells (7). Another study showed the differentiation of PBSC into mesangial cells from 2 weeks after BMT, even in healthy mice
